Literature DB >> 3511808

Drug-induced pulmonary disease. Part 1: Cytotoxic drugs.

J A Cooper, D A White, R A Matthay.   

Abstract

Numerous pharmacologic agents used in the treatment of cancer have been linked to pulmonary toxic side effects. Mechanisms of damage by these drugs include direct pulmonary toxicity and indirect effects through enhancement of inflammatory reactions. Risk factors for development of pulmonary damage have been elucidated for some agents but they remain unclear for others. Clinical features are similar for most categories of cytotoxic agents, and the most common associated clinical syndrome is chronic pneumonitis/fibrosis. Treatment and outcome vary with each particular agent. In Part 1 of this review, clinical aspects and pathogenic mechanisms of cytotoxic drug-induced pulmonary disease are discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3511808     DOI: 10.1164/arrd.1986.133.2.321

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  67 in total

Review 1.  The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction.

Authors: 
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

2.  Drug-associated acute lung injury: a population-based cohort study.

Authors:  Rajanigandha Dhokarh; Guangxi Li; Christopher N Schmickl; Rahul Kashyap; Jyoti Assudani; Andrew H Limper; Ognjen Gajic
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

3.  Prevention of bleomycin-induced pulmonary fibrosis after adenovirus-mediated transfer of the bacterial bleomycin resistance gene.

Authors:  P L Tran; J Weinbach; P Opolon; G Linares-Cruz; J P Reynes; A Grégoire; E Kremer; H Durand; M Perricaudet
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

4.  Lysis pneumonopathy associated with the use of fludarabine phosphate.

Authors:  J J Crowley; L Knight; N Charan
Journal:  West J Med       Date:  1994-12

Review 5.  Cyclophosphamide toxicity. Characterising and avoiding the problem.

Authors:  L H Fraiser; S Kanekal; J P Kehrer
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

6.  The potential role of BAX and BCL-2 expression in diffuse alveolar damage.

Authors:  D Guinee; E Brambilla; M Fleming; T Hayashi; M Rahn; M Koss; V Ferrans; W Travis
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

7.  Circulating KL-6 levels in patients with drug induced pneumonitis.

Authors:  H Ohnishi; A Yokoyama; Y Yasuhara; A Watanabe; T Naka; H Hamada; M Abe; K Nishimura; J Higaki; J Ikezoe; N Kohno
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

8.  Lipidomics revealed idiopathic pulmonary fibrosis-induced hepatic lipid disorders corrected with treatment of baicalin in a murine model.

Authors:  Changfeng Hu; Yiqi Wang; Yongsheng Fan; Haichang Li; Chunyan Wang; Jida Zhang; Shuijuan Zhang; Xianlin Han; Chengping Wen
Journal:  AAPS J       Date:  2015-03-12       Impact factor: 4.009

9.  Modulation of cyclophosphamide-induced early lung injury by curcumin, an anti-inflammatory antioxidant.

Authors:  N Venkatesan; G Chandrakasan
Journal:  Mol Cell Biochem       Date:  1995-01-12       Impact factor: 3.396

10.  Cyclophosphamide induced early biochemical changes in lung lavage fluid and alterations in lavage cell function.

Authors:  N Venkatesan; G Chandrakasan
Journal:  Lung       Date:  1994       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.